^
    Back
    Association details:
    Biomarker:PTEN expression
    Cancer:Salivary Gland Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2019
    Title:

    TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH ADVANCED HER2–POSITIVE SALIVARY DUCT CARCINOMA: EXPLORATORY BIOMARKER ANALYSES

    Published date:
    09/30/2019
    Excerpt:
    Treatment response (PR or CR vs. SD or PD) and PTEN IHC score (1+ – 3+ vs. 0) were related with favorable PFS (hazard ratio [HR], 0.25 and 0.39, respectively) and OS (HR, 0.29 and 0.36, respectively)...PTEN and mTOR can serve as predictive biomarkers in patients with advanced SDC treated with trastuzumab plus docetaxel. Serum CRP level may predict survival of this population.
    DOI:
    10.1093/annonc/mdz252